Drugs / JY028
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03725566 | May 2018 → May 2020 | macular degeneration | Beijing Tongren Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JY028 | “to rearch the safety and tolerance of JY028 injection” NCT03725566 ↗ |
| Action | Inhibit | “anti-VEGF monoclonal antibody” NCT03725566 ↗ |
| Modality | Monoclonal antibody | “Recombinant Humanized Anti-vegf Monoclonal Antibody” NCT03725566 ↗ |
| Route | Intravitreal | “by intravitreous injection” NCT03725566 ↗ |